S. Murray Sherman to Molecular Targeted Therapy
This is a "connection" page, showing publications S. Murray Sherman has written about Molecular Targeted Therapy.
Connection Strength
0.375
-
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
Score: 0.375
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.